Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An eastern cooperative oncology group randomized study

Journal of the National Cancer Institute

Volumn 84, Issue 14, 1992, Pages 1077-1084

  Ettinger, David S ^a   Finkelstein, Dianne M ^b   Abeloff, Martin D ^a   Skeel, Roland T ^c   Stott, Phillip B ^d   Frontiera, Michael S ^e   Bonomi, Phillip D ^f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d Borgess Hospital   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MENOGARIL; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; LUNG NEOPLASMS; MALE; MENOGARIL; NEOPLASM STAGING; NOGALAMYCIN; SUPPORT, U.S. GOV'T, P.H.S.; VINCRISTINE;

EID: 0026720037     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.14.1077     Document Type: Article

References (26)

1. Joss RA, Cavalu F, Goldhirsch A, et al: New drugs in small-cell lung cancer. Cancer Treat Rev 13:157–176, 1986
2. Seifter EJ, Ihde D: Therapy of small cell lung cancer A perspective on two decades of clinical research. Semin Oncol 15:278–299, 1988
3. Issell BF, Einhorn LH, Comis RL, et al: Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat Rep 69:127–128, 1985
4. Johnson DH, Hainsworth JD, Hande KR, et al: Current status of etoposide in the management of small cell lung cancer. Cancer 67 (suppl):231–244, 1991
5. Clark P, Talbot D, Price C, et al: Single agent etoposide in untreated extensive small cell lung cancer. Lung Cancer 4:A108, 1988
6. Creech RH, Tritchler D, Ettinger DS, et al: Phase II study of PALA, amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST 2579). Cancer Treat Rep 68:1183–1184, 1984
7. Pedersen AG, Bork E, Osterlind K, et al: Phase II study of teniposide in small cell carcinoma of the lung. Cancer Treat Rep 68:1289–1291, 1984
8. Bork E, Hansen M, Dombernowsky P, et al: Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer: Results of a phase II trial in untreated patients. J Clin Oncol 4:524–527, 1986
9. Aisner J: Identification of new drugs in small cell lung cancer. Phase II agents first? Cancer Treat Rep 71:1131–1133, 1987
10. Cullen M: Evaluating new drugs in patients with chemosensitive tumors: Ethical dilemmas in extensive small cell lung cancer. Lung Cancer 5:1–7, 1989
11. Giaccone G: Identification of new drugs in pretreated patients with small cell lung cancer. Eur J Cancer Clin Oncol 25:411–413, 1989
12. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer Its time has come. J Clin Oncol 8:374–377, 1990
13. Simon RM: Design and conduct of clinical trials. In Cancer, Principles and Practice of Oncology (DeVita VT Jr, Hellman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1989, pp 396–420
14. Jackson D, Cruz J, White D, et al: Cisplatin in extensive small-cell lung cancer (SCLC): A randomized trial by the Piedmont Oncology Association. Proc ASCO 8:222, 1989
15. Giaconne G, Donadio M, Bonardi G, et al: Teniposide in the treatment of small-cell lung cancer: The influence of prior chemotherapy. J Clin Oncol 6:1264–1270, 1988
16. Bork E, Hansen M, Ersbol J, et al: A study of teniposide (VM-26) versus vepeside (VP-16) as single agents in previously untreated patients with small cell lung cancer (SCLC) >70 years. Proc ASCO 8:229, 1989
17. Cohen EA, Gralla RJ, Kris MG, et al: Phase II studies in small cell lung cancer (SCLC): An analysis of 97 trials. Proc ASCO 4:190, 1985
18. Evans WK, Eisenhauer E, Cormier Y, et al: Phase II study of amonafide: Results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8:390–395, 1990
19. Blackstein M, Eisenhauer E, Wierzbicki R, et al: Epirubicin in extensive small-cell lung cancer: A phase II study in previously untreatedpatients: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 8:385–389, 1990
20. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
21. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230–240, 1990
22. Adams EG, Crampton SL, Bhuyan BK: Effect of 7-con-O- methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells. Cancer Res 41:4981–4987, 1981
23. Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin. Cancer Treat Rep 63:1971–1978, 1979
24. McGovren JP, Neil GL, Delinger RH, et al: Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res 39:4349–4855, 1979
25. Broder LE, Cohen MH, Selawry OS: Treatment of bronchogenic carcinoma. n. Small cell. Cancer Treat Rev 4:219–260, 1977
26. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3:65–71, 1985